Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-301 in HER2-positive advanced or metastatic salivary gland tumor
KCT0007106Phase 2Withdrawn
- Sponsor
- Aston Sci
- Start
- Oct 2025
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HER2 ICD vaccine in salivary gland cancer (SGC), sponsored by Aston Sci. Planned start Oct 2025; status: withdrawn.
02
Drugs
HER2 ICD vaccine
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on KCT0007106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007106.